Improving outcomes for patients with chronic hepatitis B

被引：16

作者：

Gish R.G. ^{[1
]}

机构：

[1] Department of Medicine, Division of Hepatology and Complex GI, California Pacific Medical Center, San Francisco, CA 94115

来源：

Current Gastroenterology Reports | 2007年 / 9卷 / 1期

关键词：

Lamivudine; Adefovir; Entecavir; HBeAg Seroconversion; Adefovir Dipivoxil;

D O I：

10.1007/s11894-008-0016-9

中图分类号：

学科分类号：

摘要：

The ultimate goal in managing patients with chronic hepatitis B (CHB) is to improve long-term outcomes by decreasing deaths and liver transplantation procedures due to hepatitis B virus (HBV)-related cirrhosis and hepatocellular carcinoma. Active intervention and vaccination of individuals susceptible to HBV infection are key steps to decrease the risk of this global public health problem. Large studies have demonstrated that longterm outcomes of CHB are tied to serum levels of HBV DNA. New oral treatments, characterized by potent antiviral effects, good tolerability, improved histology, stable seroconversion, and minimal resistance, are available. Long-term data with oral medications have shown decreased rates of liver cancer development, liver disease reversal, and progression to liver failure. Pegylated interferon trials have demonstrated modest rates of hepatitis B e antigen seroconversion and improved histology after treatment. This paper describes ways to improve outcomes of CHB using vaccines, interferon, lamivudine, adefovir, and newer agents. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：14 / 22

页数：8

共 52 条

[1]

Lavanchy D., Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures, J Viral Hepat, 11, pp. 97-107, (2004)

[2]

Gish R.G., Gadano A.C., Chronic hepatitis B: Current epidemiology in the Americas and implications for management, J Viral Hepat, (2006)

[3]

Ganem D., Prince A.M., Hepatitis B virus infection - Natural history and clinical consequences, N Engl J Med, 350, pp. 1118-1129, (2004)

[4]

(2006)

[5]

Dienstag J.L., Cianciara J., Karayalcin S., Et al., Durability of serologic response after lainivadine treatment of chronic hepatitis B, Hepatology, 37, pp. 748-755, (2003)

[6]

Fung S.K., Wong F., Hussain M., Lok A.S., Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B, J Viral Hepat, 11, pp. 432-438, (2004)

[7]

Bartholomeusz A., Locarnini S.A., Antiviral drug resistance: Clinical consequences and molecular aspects, Semin Liv Dis, pp. 162-170, (2006)

[8]

Fung S.K., Andreone P., Han S.H., Et al., Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation, J Hepatol, 43, pp. 937-943, (2005)

[9]

Hoofnagle J.H., DiBisceglie A.M., The treatment of chronic viral hepatitis, N Engl J Med, 336, pp. 347-356, (1997)

[10]

Cihlar T., Lin D.C., Pritchard J.B., Et al., The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1, Mol Pharmacol, 56, pp. 570-580, (1999)

← 1 2 3 4 5 6 →